Merck & Co. & Donald Trump

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

Donald Trump: Donald Trump>>>'s administration has been criticized for cuts to foreign aid and withdrawal from the World Health Organization>>>, which experts say have weakened global health response capabilities, though he has expressed concern about the outbreak and pledged some funding.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Donald Trump: Donald Trump>>>'s administration's past decision to withdraw from the World Health Organization>>> and cut foreign aid was criticized for weakening surveillance systems.

Merck & Co.: Merck & Co. saw its stock price rise, contributing to the gains in the Dow Jones Industrial Average.

Donald Trump: President Donald Trump stated that the U.S. and Iran still have issues to resolve in their negotiations.

Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.

Merck & Co.: Merck & Co., a hepatitis B vaccine maker, expressed deep concern over the ACIP's vote, and its shares closed down 1.2% on Friday.